Content about Respiratory diseases

May 21, 2012

DSN recently talked with COPD Foundation founder and president John Walsh about the organization's new leadership. In March, the COPD Foundation took over leadership for Drive4COPD, which aims to screen people for chronic obstructive pulmonary disease, a collective term for emphysema and chronic bronchitis, which the group estimates to affect 24 million Americans who may have it but don't know it.

AUDIO Q&A: DSN recently talked with COPD Foundation founder and president John Walsh about the organization's new leadership. In March, the COPD Foundation took over leadership for Drive4COPD, which aims to screen people for chronic obstructive pulmonary disease, a collective term for emphysema and chronic bronchitis, which the group estimates to affect 24 million Americans who may have it but don't know it.

January 27, 2014

The Food and Drug Administration will hold a public meeting of the Allergenic Products Advisory Committee on Tuesday to determine the safety and efficacy of Ragwitek, a short ragweed pollen allergen extract tablet for sublingual use.

ARLINGTON HEIGHTS, Ill. — The Food and Drug Administration will hold a public meeting of the Allergenic Products Advisory Committee on Tuesday to determine the safety and efficacy of Ragwitek, a short ragweed pollen allergen extract tablet for sublingual use, which is manufactured by Merck and indicated for immunotherapy for diagnosed ragweed pollen induced allergic rhinitis, with or without conjunctivitis.

December 18, 2013

Four school districts have won a competition sponsored by Mylan to raise awareness about dangerous allergic reactions, the company said.

PITTSBURGH — Four school districts have won a competition sponsored by Mylan to raise awareness about dangerous allergic reactions, the company said Wednesday.

Mylan, whose Mylan Specialty division makes the EpiPen injector pen for severe allergic reactions, known as anaphylaxis, announced the winners of the Raise Your Hand for Anaphylaxis Awareness competition, for which it hired actress Julie Bowen as a celebrity spokeswoman.

November 14, 2013

New legislation signed into law Wednesday encourages states to adopt laws allowing schools to maintain a supply of emergency treatments for life-threatening allergy attacks.

NEW YORK — New legislation signed into law Wednesday encourages states to adopt laws allowing schools to maintain a supply of emergency treatments for life-threatening allergy attacks.

Barack Obama signed the School Access to Emergency Epinephrine Act, under which schools could maintain a supply of epinephrine, which is the only first-line treatment for life-threatening allergic reactions, also known as anaphylaxis.

The legislation received praise from Mylan, a drug maker that produces EpiPen, a popular epinephrine injector pen.

October 21, 2013

Nearly 1-in-50 people in the United States are at risk of severe allergic reactions, according to a new study announced Monday by the Asthma and Allergy Foundation of America.

WASHINGTON — Nearly 1-in-50 people in the United States are at risk of severe allergic reactions, according to a new study announced Monday by the Asthma and Allergy Foundation of America.

According to the study, severe, life-threatening allergic reactions known as anaphylaxis are common in the United States, occurring in about 1.6% of the population. The rate, the study said, is probably higher, and closer to 5.1%. The study was published in the Journal of Allergy and Clinical Immunology.

August 20, 2013

A majority of respondents to a survey commissioned by drug maker Sanofi say that they or their children experienced a severe allergic reaction while traveling.

BRIDGEWATER, N.J. — A majority of respondents to a survey commissioned by drug maker Sanofi say that they or their children experienced a severe allergic reaction while traveling.

August 14, 2013

In its first year, more than 20,000 schools across all 50 states participated in the program that offers four free EpiPen or EpiPen Jr (epinephrine) Auto-Injectors to qualifying schools in the United States.

BASKING RIDGE, N.J. — Mylan Specialty, the fully integrated specialty pharmaceutical business of Mylan, today announced a second year of its EpiPen4Schools program. In its first year, more than 20,000 schools across all 50 states participated in the program that offers four free EpiPen or EpiPen Jr (epinephrine) Auto-Injectors to qualifying schools in the United States. Qualifications include having a valid prescription.

June 18, 2013

A division of Mylan is hiring NFL player Adrian Peterson and family expert Jo Frost to promote an emergency treatment for severe allergic reactions.

BASKING RIDGE, N.J. — A division of Mylan is hiring NFL player Adrian Peterson and celebrity nanny Jo Frost to promote an emergency treatment for severe allergic reactions.

Mylan Specialty announced that it had hired the two — who both have potentially life-threatening allergies — to raise awareness of the problem. Mylan Specialty is launching a multichannel marketing campaign for the EpiPen (epinephrine) auto-injector to mark the 25th anniversary of its approval by the Food and Drug Administration.

May 21, 2013

A subsidiary of drug maker Mylan is sponsoring a campaign to draw attention to severe allergic reactions.

BASKING RIDGE, N.J. — A subsidiary of drug maker Mylan is sponsoring a campaign to draw attention to severe allergic reactions.

Mylan Specialty announced the Raise Your Hand for Anaphylaxis Awareness campaign, hiring actress Julie Bowen as a celebrity spokeswoman. The campaign will invite people to virtually "raise their hands" for their school districts by visiting www.Anaphylaxis101.com; four winning school districts will receive grants of $15,000 to support educational programs.

February 20, 2013

A division of drug maker Mylan has distributed auto-injectors of an emergency drug used for severe allergic reactions to schools nationwide.

BASKING RIDGE, N.J. — A division of drug maker Mylan has distributed autoinjectors of an emergency drug used for severe allergic reactions to schools nationwide.

Mylan Specialty said Wednesday that since its August 2012 launch of the EpiPen4Schools program, thousands of schools around the country had elected to participate and receive free EpiPen and EpiPen Jr (epinephrine) auto-injectors. The program was launched to help schools have improved access to epinephrine in the event that a person experiences a life-threatening allergic reaction, also known as anaphylaxis.

January 29, 2013

Sanofi announced today that Auvi-Q (epinephrine injection, USP) is now available in U.S. retail pharmacies nationwide with a prescription from a healthcare provider.

BRIDGEWATER, N.J. — Sanofi announced today that Auvi-Q (epinephrine injection, USP) is now available in U.S. retail pharmacies nationwide with a prescription from a healthcare provider.

 

January 24, 2013

A division of drug maker Teva is partnering with an advocacy group focused on asthma in the launch of a new educational website about the condition.

WASHINGTON — A division of drug maker Teva Pharmaceutical Industries is partnering with an advocacy group focused on asthma in the launch of a new educational website about the condition.

The Asthma and Allergy Foundation of America and Teva Respiratory announced the launch of Get Smart About Asthma, which aims to increase understanding of how inflammation in the airways contributes to the disease's persistence and severity, as well as providing other educational materials.

January 14, 2013

Egg allergies may no longer be a valid reason to not get a flu shot, the American College of Allergy, Asthma and Immunology announced Friday.

ARLINGTON HEIGHTS, Ill. — Egg allergies may no longer be a valid reason to not get a flu shot, the American College of Allergy, Asthma and Immunology announced Friday. 

September 26, 2012

Mylan Specialty has hired a star of a popular TV series as a celebrity spokeswoman for a campaign designed to draw attention to severe allergic reactions.

BASKING RIDGE, N.J. — Mylan Specialty has hired a star of a popular TV series as a celebrity spokeswoman for a campaign designed to draw attention to severe allergic reactions.

July 24, 2012

The Food and Drug Administration has approved a new drug made by Forest Labs for treating chronic obstructive pulmonary disease, the agency said.

SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug made by Forest Labs for treating chronic obstructive pulmonary disease, the agency said.

The FDA announced the approval of Tudorza Pressair (aclidinium bromide) for the long-term maintenance of COPD-related narrowing of the airways in the lung, also known as bronchospasm. The drug is an inhaled dry powder used twice per day.

July 13, 2012

GlaxoSmithKline and Theravance submitted a regulatory application to the Food and Drug Administration for their chronic obstructive pulmonary disease treatment.

LONDON and SOUTH SAN FRANCISCO, Calif. — GlaxoSmithKline and Theravance submitted a regulatory application to the Food and Drug Administration for their chronic obstructive pulmonary disease treatment.

June 21, 2012

Taken together, asthma and chronic obstructive pulmonary disease — which includes chronic bronchitis and emphysema — affect nearly 50 million Americans, or about 15% of the total U.S. population, according to statistics from such organizations as the Centers for Disease Control and Prevention.

Taken together, asthma and chronic obstructive pulmonary disease — which includes chronic bronchitis and emphysema — affect nearly 50 million Americans, or about 15% of the total U.S. population, according to statistics from such organizations as the Centers for Disease Control and Prevention. And combined, the two diseases cause more than 100,000 deaths per year. Fortunately, however, there is a wide range of treatments available for both, many of which work for both diseases.


June 21, 2012

Drug Store News recently talked with COPD Foundation founder and president John Walsh about the organization’s new leadership. In March, the COPD Foundation took over leadership for Drive4COPD, which aims to screen people for chronic obstructive pulmonary disease, a collective term for emphysema and chronic bronchitis, which the group estimates to affect 24 million Americans who may have it but don’t know it.


Drug Store News recently talked with COPD Foundation founder and president John Walsh about the organization’s new leadership. In March, the COPD Foundation took over leadership for Drive4COPD, which aims to screen people for chronic obstructive pulmonary disease, a collective term for emphysema and chronic bronchitis, which the group estimates to affect 24 million Americans who may have it but don’t know it.


DSN: What led the COPD Foundation to take over Drive4COPD?


May 29, 2012

A unit of generic drug maker Mylan has settled with Sunovion Pharmaceuticals over a drug used to treat chronic obstructive pulmonary disease and asthma.

PITTSBURGH — A unit of generic drug maker Mylan has settled with Sunovion Pharmaceuticals over a drug used to treat chronic obstructive pulmonary disease and asthma.

Mylan announced Tuesday that it had reached a settlement in a patent litigation suit that Sunovion, which used to operate under the name Sepracor, had filed against Dey Pharma, now known as Mylan Specialty, concerning the drug Xopenex (levalbuterol hydrochloride).

May 23, 2012

Taken together, asthma and chronic obstructive pulmonary disease — which includes chronic bronchitis and emphysema — affect nearly 50 million Americans, or about 15% of the total U.S. population, according to statistics from such organizations as the Centers for Disease Control and Prevention. And combined, the two diseases cause more than 100,000 deaths per year. Fortunately, however, there is a wide range of treatments available for both, many of which work for both diseases.

Taken together, asthma and chronic obstructive pulmonary disease — which includes chronic bronchitis and emphysema — affect nearly 50 million Americans, or about 15% of the total U.S. population, according to statistics from such organizations as the Centers for Disease Control and Prevention. And combined, the two diseases cause more than 100,000 deaths per year. Fortunately, however, there is a wide range of treatments available for both, many of which work for both diseases.

March 29, 2012

A nonprofit organization focused on chronic obstructive pulmonary disease will take over a COPD awareness campaign from the drug company that started it.

WASHINGTON — A nonprofit organization focused on chronic obstructive pulmonary disease will take over a COPD awareness campaign from the drug company that started it.

The COPD Foundation said it would lead the Drive4COPD campaign — originally started by Boehringer Ingelheim Pharmaceuticals in 2010 to screen people for the disease with the assumption that 24 million Americans may have it but are not aware. BI will continue to provide funding for the program.

March 29, 2012

Regulators will take a few months longer to review the approval application for a new drug for treating chronic obstructive pulmonary disease, the drug's developers said Thursday.

NEW YORK — Regulators will take a few months longer to review the approval application for a new drug for treating chronic obstructive pulmonary disease, the drug's developers said Thursday.

Forest Labs and Almirall said the Food and Drug Administration would require a three-month extension to complete its review of their application for aclidinium bromide, a maintenance drug for COPD. The FDA plans to complete its review and decide whether or not to approve the drug in July.

March 20, 2012

Novartis has launched a new treatment for chronic obstructive pulmonary disease, the drug maker said Monday.

EAST HANOVER, N.J. — Novartis has launched a new treatment for chronic obstructive pulmonary disease, the drug maker said Monday.

Novartis Pharmaceuticals, the U.S. division of the Swiss drug manufacturer, announced the launch of Arcapta Neohaler (indacaterol inhalation powder) in the 75-mcg strength. The Food and Drug Administration approved the drug last July.

February 2, 2012

More than 50 drugs are under development for treating a respiratory disease that is the third-leading cause of death in the United States.

WASHINGTON — More than 50 drugs are under development for treating a respiratory disease that is the third-leading cause of death in the United States.

The Pharmaceutical Research and Manufacturers of America released a list Thursday of 54 drugs in clinical development for chronic obstructive pulmonary disease, or COPD.

October 4, 2011

Growing numbers of Americans with asthma and chronic obstructive pulmonary disease are driving innovation among drug makers, according to a new report by Frost & Sullivan.

MOUNTAIN VIEW, Calif. — Growing numbers of Americans with asthma and chronic obstructive pulmonary disease are driving innovation among drug makers, according to a new report by Frost & Sullivan.